Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

New study sets standard blood levels for stroke prevention drugs in chinese patients

NCT ID NCT04611893

Knowledge-focused Sponsor: Chinese University of Hong Kong Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study measured the amount of common blood thinners (dabigatran, apixaban, and rivaroxaban) in the blood of 308 Chinese adults with atrial fibrillation who had been taking the medication for at least 3 months. The goal was to establish normal reference ranges for these drugs in this specific ethnic group, which can help doctors better monitor and adjust treatment. Participants had their blood tested before and after taking their medication.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

308 people

The number who actually took part.

Started

Nov 2020

Finished

Jun 2025

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

Patients who are on dabigatran, apixaban and rivaroxaban based on the above inclusion and exclusion criteria will be recruited from the Prince of Wales Hospital, either in-patient or out-patient clinic.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Accepted

You do not need to have the condition being studied to take part.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: 1. Ethnic Chinese ONLY 2. 18 years old or above 3. Non-valvular atrial fibrillation 4. Duration of NOAC use at least 3 months 5. No changes in NOAC dosage or type within 3 months 6. Creatinine Clearance (by Cockcroft-Gault formula) \>/=30mL/min Exclusion Criteria: 1. Valvular atrial fibrillation or no atrial fibrillation 2. Recent haemorrhage or ischemia within 1 year 3. Active liver disease 4. Abnormal baseline clotting profile 5. Abnormal baseline thrombocytopenia or thrombocytosis 6. Thromboembolic tendency other than atrial fibrillation (e.g. antiphospholipid syndrome, protein C, S, anti-thrombin III deficiency) 7. Non-compliant patients, defined as missing any doses of NOAC in recent 1 month 8. Anticoagulation for disorders other than AF 9. Pregnancy

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Ischemic are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

atrial fibrillation ischemic disease ischemic stroke stroke disorder

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Ischemic Ischemic stroke Stroke syndrome Stroke, acute

Contacts and locations

Locations

  • Chinese University of Hong Kong

    Hong Kong, Hong Kong

More trials for these conditions

Other studies related to the condition(s) this trial covers.